Incretin Atlas › Trials › Phase 2b
Phase 2b
Efinopegdutide · MASH F2–F3
Design
- Molecule(s)
- Efinopegdutide
- Population
- MASH F2–F3
- Official title
- A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
- Sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 2
- Registry status
- completed · 2023-06 → 2025-12
- Participants
- 386
- Duration
- 52 weeks
- Registry
- NCT05877547
Outcomes in the indication
Phase 2b Efinopegdutide · MASH F2–F3 · 52 weeks · n = 386 abstract
MASH resolution without worsening of fibrosis +43.0 / +49.5 / +47.8 percentage points vs placebo (4 / 7 / 10 mg); fibrosis improvement +21.7 / +30.4 / +13.0 (10 mg not significant). Open-label semaglutide 2.4 mg arm: 53 % and 25 %.
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| MASH resolution without worsening of fibrosis 4 mg week 52 | +56.0 | +13.0 | +43.0 (+25.7 to +57.8) percentage points | abstract |
| MASH resolution without worsening of fibrosis 7 mg week 52 | +63.0 | +13.0 | +49.5 (+31.4 to +64.2) percentage points | abstract |
| MASH resolution without worsening of fibrosis 10 mg week 52 | +61.0 | +13.0 | +47.8 (+30.7 to +62.0) percentage points | abstract |
| Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 4 mg week 52 | +43.0 | +21.0 | +21.7 (+7.1 to +35.7) percentage points | abstract |
| Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 7 mg week 52 | +52.0 | +21.0 | +30.4 (+15.4 to +44.3) percentage points | abstract |
| Fibrosis improvement (≥1 stage) without worsening of steatohepatitis 10 mg week 52 | +34.0 | +21.0 | +13.0 (−1.2 to +26.8) percentage points | abstract |
Verbatim quotes (6)
- MASH resolution without worsening of fibrosis
difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
- MASH resolution without worsening of fibrosis
difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
- MASH resolution without worsening of fibrosis
difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg
- Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group
- Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group
- Fibrosis improvement (≥1 stage) without worsening of steatohepatitis
difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group
Primary sources
- Lawitz E, Wong VW, Shankar RR, Francque S, Patel K, Miele L, et al. Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study. Lancet. 2026. PMID: 43003105.
- Merck Sharp & Dohme LLC. A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis. ClinicalTrials.gov identifier NCT05877547. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05877547
How to cite this page
Medical Adviser's Group. Incretin Atlas: Phase 2b. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.